• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.37 -0.24 (-1.90%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,058,829
Open 12.37
Bid (Size) 11.98 (100)
Ask (Size) 12.15 (500)
Prev. Close 12.61
Today's Range 12.26 - 12.84
52wk Range 2.745 - 15.02
Shares Outstanding 287,686,199
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
October 08, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
October 01, 2026
From AbCellera Biologics Inc.
Via Business Wire

Performance

52-Week Range 17.6% below 52-week high
12.37
2.7552W Low 15.0252W High
1 Week 5.2% below 1-week high
11.891W Low 13.051W High

AbCellera Biologics Inc. - Common Shares (ABCL) traded between $2.75 and $15.02 over the past 52 weeks and last traded at $12.37, 17.6% below its 52-week high. Over the past week it ranged between $11.89 and $13.05.

Past 12 Months
+2.9%
+10.7%
+83.5%
+220.5%
+260.6%
+120.1%
1W +$0.35
1M +$1.20
3M +$5.63
6M +$8.51
YTD +$8.94
1Y +$6.75

ABCL was +120.1% over the past year, +220.5% over six months, +260.6% year to date, +2.9% in the last week.

12 Months vs Market
ABCL
+120.1%
DIA
+11.4%
SPY
+16.2%
QQQ
+21.9%
IWM
+9.5%

Over the past 12 months ABCL returned +120.1% versus DIA (Dow) +11.4%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +21.9% and IWM (Russell 2000) +9.5%.

Volume & Liquidity 0.46× 3-mo avg
Today 3,058,829 3-mo avg 6.6M
1W
5.0M
1M
5.4M
3M
6.6M
6M
7.3M
YTD
6.1M
1Y
5.7M

ABCL most recently traded 3,058,829 shares against a 3-month average daily volume of 6.6M.

More News

Read More
News headline image
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
September 16, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
September 02, 2026
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗
August 05, 2026
Via Chartmill
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
August 19, 2026
From USA News Group
Via GlobeNewswire
News headline image
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
August 13, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera (ABCL) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
August 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
Here are the top movers in Monday's session. ↗
August 10, 2026
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
August 10, 2026
Via Chartmill
News headline image
AI Found an Influenza Target That Survives Viral Mutation
August 10, 2026
From Equity Insider
Via GlobeNewswire
News headline image
AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗
August 10, 2026
Via MarketBeat
News headline image
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
August 10, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
August 07, 2026
Via Benzinga
Get insights into the top gainers and losers of Friday's after-hours session. ↗
August 07, 2026
Via Chartmill
News headline image
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
August 07, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
News headline image
AbCellera Reports Q2 2026 Business Results
August 05, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
July 29, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
July 07, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
July 06, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
June 05, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
June 04, 2026
Via MarketBeat

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 12.37
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 10/14/26 04:00 PM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 3.56B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap